



(12) Translation of
European patent specification

(11) NO/EP 2434891 B1

NORWAY

(19) NO
(51) Int Cl.
A01N 43/42 (2006.01)
A61K 31/44 (2006.01)
C07D 471/04 (2006.01)

Norwegian Industrial Property Office




(45)	Translation Published	2020.11.23
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.07.22
(86)	European Application Nr.	10781238.0
(86)	European Filing Date	2010.05.27
(87)	The European Application's Publication Date	2012.04.04
(30)	Priority	2009.05.27, US, 181653 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	PTC Therapeutics, Inc., 100 Corporate Court, Middlesex Business Center, South Plainfield, NJ 07080, USA
(72)	Inventor	ALMSTEAD, Neil, 179 Longview Dr., PrincetonNJ 08540, USA ARASU, Tamil, 67 Proctor St., EdisonNJ 08817, USA CHOI, Soongyu, 44 Durham Road, SkillmanNJ 08502, USA CAO, Liangxian, 6 Mioduski Court, ParlinNJ 08859, USA CAMPBELL, Jeff, 13 Annabella Ln., Hilton Head IslandSC 29926-1876, USA CORSON, Don, 2244 Cottonwood Place, ErieCO 80516, USA DAVIS, Thomas, W., 268 Prospect Street, South OrangeNJ 07079, USA GRACI, Jason, D., 826 Palm St., ScrantonPA 18505, USA GU, Zhengxian, 73 York Drive, PrincetonNJ 08540, USA HWANG, Peter, Seongwoo, 227 Suttons Lane, EdisonNJ 08817, USA LENNOX, William, 184 Hillside Ave., BedminsterNJ 07921, USA MIAO, Harry, H., 3 Colonial Court, EdisonNJ 08820, USA MILLER, Langdon, 13 Strawberry Lane, LebanonNJ 08833, USA MOON, Young-Choon, 11 Edgewood Drive, Belle MeadNJ 08502, USA QI, Hongyan, 30 Birch Dr., PlainsboroNJ 08536, USA TROTТА, Christopher, 198 Scobee Lane, SomersetNJ 08873, USA WEETALL, Marla, L., 70 Burnham Parkway, MorristownNJ 07960, USA
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge


(54) Title **METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS**


(56) References
Cited: WO-A1-2005/089764







US-A1- 2005 282 849
US-A1- 2009 017 021
WO-A1-2008/127714
WO-A1-2007/002051
WO-A1-2006/015035


Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>












Patentkrav**1. Forbindelse som har formelen:**




















 1228	 1229	
 1230	 1231	 1234
 1235	 1250	 1255
 1257	 1258	 1259






















































 1553	 1555	
 1557	 1558	 1559
 1560	 1561	 1562
 1563	 1564	 1565

 1566	 1567	 1568
 1569	 1570	 1571
 1572	 1577	 1578
 1580	 1581	 1604
 1605	 1607	 1611






 1671	 1672	 1673
 1674	 1675	
 1677	 1681	 1682
 1693	 1695	
 1698	 1701	 1702
 1703	 1704	

eller et farmasøytisk akseptabelt salt derav.

2. Forbindelse ifølge krav 1 eller et farmasøytisk akseptabelt salt derav for anvendelse i en fremgangsmåte for å behandle kreft hos et menneske med behov derav, hvori kreften er akutt leukemi; akutt lymfocytisk leukemi; akutt myelocytisk leukemi; kronisk leukemi; polycytemia vera; lymfom; eller multippelt myelom.


5

3. Forbindelsen for anvendelse ifølge krav 2, hvori forbindelsen er



eller et farmasøytisk akseptabelt salt derav.

10 4. Forbindelsen




eller et farmasøytisk akseptabelt salt derav for anvendelse i en fremgangsmåte for å behandle kreft hos et menneske med behov derav, hvori kreften er akutt leukemi; akutt lymfocytisk leukemi; akutt myelocytisk leukemi; kronisk leukemi; polycytemia vera; lymfom; eller multippelt myelom.

15

5. Farmasøytisk sammensetning omfattende forbindelsen ifølge krav 1 i blanding med ett eller flere farmasøytisk akseptable hjelpestoffer.

20 6. Den farmasøytiske sammensetningen ifølge krav 5 for anvendelse i en fremgangsmåte for å behandle kreft hos et menneske med behov derav, hvori kreften er en solid tumorkreft; eller hvori kreften er akutt leukemi; akutt lymfocytisk leukemi; akutt myelocytisk leukemi; kronisk leukemi; polycytemia vera; lymfom; eller multippelt myelom.

25 7. Farmasøytisk sammensetning omfattende forbindelsen



eller et farmasøytisk akseptabelt salt derav i blanding med ett eller flere farmasøytisk
akseptable hjelpestoffer for anvendelse i en fremgangsmåte for å behandle kreft hos et
menneske med behov derav, hvori kreften er akutt leukemi; akutt lymfocytisk leukemi; akutt
5 myelocytisk leukemi; kronisk leukemi; polycytemia vera; lymfom; eller multippelt myelom.